Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter
Biotech Stock Gets Booted in Latest Fund Update Bain Capital sold its entire stake in Nuvalent stock during the third quarter.
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock Bain Capital completely exited its position in Disc Medicine stock during the third quarter
Why Bain Capital Is Selling Shares of This Biotech Stock Now Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.
Which stocks are moving on Friday? Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
Let's uncover which stocks are experiencing notable gaps during today's session. There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics Deal The company is getting deeper into the antiviral space, buying a company working on a long-acting drug to protect against flu.
Discover the top movers in Friday's pre-market session. Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
Merck To Buy Cidara In $9.2B Deal To Strengthen Antiviral Portfolio With the new deal, Merck would gain access to CD388, currently in late-stage development, and designed to prevent influenza infection in individuals at higher risk of influenza complications.
Why Is Cidara Therapeutics (CDTX) Stock Trending Overnight? Cidara Therapeutics shares jumped over 42% in after-hours trading following a 13D filing and Phase 3 enrollment milestone.
